New PET scan for pheochromocytoma
Treatments studied
Part of Cancer clinical trials.
This study uses a special PET scan (called 18F-mFBG) to get clearer pictures of pheochromocytoma, a rare adrenal tumor. It may help doctors better understand your tumor and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 80 years old and have a regular caregiver.
- You have been diagnosed with pheochromocytoma (a type of adrenal gland tumor).
- You are willing and able to understand the study details and give your permission to participate.
- You do not have serious heart, brain, liver, kidney, or blood problems.
- You do not have poorly controlled high blood pressure (above 180/110).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you have no allergies to the imaging agent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special PET/CT or SPECT/CT scans that light up certain types of tumor cells (neuroblastoma and pheochromocytoma/paraganglioma). The scans help doctors see where the cancer is, how far it has spread, and whether treatment is working.
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
This study helps doctors better understand and diagnose pheochromocytoma and paraganglioma—rare tumors that release stress hormones and cause high blood pressure and other symptoms. Researchers will study your medical history, blood and urine tests, imaging scans, and genetic information to improve how these conditions are found and understood.
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.